Pharmaceutical Technology Europe - October 2012 - (Page 2)

CROs and CMOs Have Cause to Celebrate The 2012 edition of the PharmSource–Pharmaceutical Technology Outsourcing Survey found a contract services industry that is enjoying better-thanexpected business performance in 2012, fuelled by increases in R&D spending at all levels of the bio/ pharmaceutical industry. However, the survey, administered in June 2012, indicates that the industry remains aggressive in seeking new business and is keenly aware of the risks that could change its fortunes. Bio/pharma respondents reported strong growth in their spending on contract services, with 62% reporting that spending in 2012 has increased over 2011, including 43% who said that spending has increased by 10% or more this year. One-quarter of bio/pharma respondents indicated that spending on contract services has been flat for the year, while only 12% said their spending has been down. Contract service providers have clearly been enjoying the 2012 spending boom. Among CRO and CMO respondents to the survey, 39% reported that business in 2012 will be “extremely good” or “very good,” which is double the share of respondents reporting such robust performance in past years’ surveys. Only 5% indicated that business will be “not be very good,” which is well below the 20%-plus who gave that answer in each of the previous three years. Jim Miller 2 OUTSOURCING 11 REGULATORY COOPERATION 7 QUALITY BY DESIGN 12 COCRYSTALS 8 NEWS 13 BLOGS 10 ENERGY EFFICIENCY 15 STAFF

Table of Contents for the Digital Edition of Pharmaceutical Technology Europe - October 2012

Pharmaceutical Technology Europe - October 2012
Contents
Cover Story: CROs and CMOs Have Cause to celebrate Annual survey shows growth for outsourcing providers
Quality by Design: A Contract Organisation’s Perspective on Overcoming Obstacles to Implementing QbD
News Bites and Trends on Twitter
Outsourcing Pharmaceutical Infrastructure Operations
EMA Focuses on Greater International Collaboration
Producing Cocrystals
Blogs: Sanofi job cuts; confidential data risk; Alzheimer’s research; and patent cliff.

Pharmaceutical Technology Europe - October 2012